Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab + Bendamustine + Prednisone in Refractory Multiple Myeloma
NCT04083898Phase 1Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Apr 2020
- Primary completion
- Mar 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of isatuximab in multiple myeloma (MM) (4 arms), sponsored by Washington University School of Medicine. Primary endpoints: Maximum Tolerated Dose at 9 months and Overall Response Rate at 6 months. Started Apr 2020; status: terminated.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04083898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04083898.